PepGen Inc. (PEPG) Stock Profile — Insider Trades & Financials

Net Income-$18.3M

EPS$-2.12

Market Cap$115.1M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

James McArthur

CEO & Executive Director

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Founded: 2018
Employees: 56
Headquarters: Boston, Massachusetts, United States

⚡

Core Efficiency

ROE?

-12.44%

ROA?

-10.55%

D/E Ratio?

0.18

📊

Profitability Ratios

Current Ratio?

11.94

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 1, 2026 (in 114 days)

Annual Report (10-K) — Based on filing pattern

Aug 1, 2026

Predicted10-K

Mar 4, 2026

10-KQ4 20256d after period end

Mar 4, 2026

10-KFY 202563d after period end

Nov 12, 2025

10-QQ3 20257d after period end

Aug 7, 2025

10-QQ2 20256d after period end

May 8, 2025

10-QQ1 20257d after period end

Feb 24, 2025

10-KQ4 20246d after period end

Feb 24, 2025

10-KFY 202555d after period end

Nov 7, 2024

10-QQ3 20246d after period end

Loading company sections...

PepGen Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness